Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Completed

Conditions studied: Myelodysplastic Syndrome

In brief

This registry is a prospective, non-interventional, post authorisation safety study for patients diagnosed with Transfusion Dependent, IPSS low or intermediate-1-Risk Myelodysplastic Syndrome (MDS), associated to a single abnormality of the chromosome 5 \[del(5q)\]. The purpose of this study is to collect additional data about the safety of an oral drug (lenalidomide, Revlimid®) that may have been prescribed to relieve anemia and decrease the need of blood transfusions. However, also patients affected by the MDS del(5q) who receive other treatments different from lenalidomide can be included in this study, if they agree.

Key facts

Study ID: NCT02279654
Run by: Celgene
People needed: 389
Starts: 2014-12-17
Expected to finish: 2022-03-29
Last updated by the study team: 2022-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Are ≥ 18 years old at the time of signing the Informed consent form (ICF)
Are transfusion dependent or have an history of transfusion dependence; for the purpose of the current Myelodysplastic syndromes (MDS) Post-authorization safety study (PASS), transfusion-dependence is defined as requiring ≥2 RBC units over an 8 week period prior to the date of signature on the ICF (due to MDS-related causes and not because of hemorrhage, trauma, or other acute cause)
Are on active treatment with lenalidomide (Lenalidomide Cohort) or have never been exposed to lenalidomide at the time of signing the ICF (Background Cohort)
Have confirmed diagnosis of IPSS low or intermediate-1-risk MDS with isolated del (5q) (with morphological and cytogenetic information) diagnosed on 15 June 2007 (date of Revlimid first approved in Europe) or later

You may not qualify if…

Refuse to participate in the Myelodysplastic syndromes (MDS) Post-authorization safety study (PASS),
Are currently participating in an interventional therapeutic clinical trial for MDS (except for erythropoiesis-stimulating agents [ESAs] and granulocyte colonystimulating growth factors)
Receive any investigational agent the time of signing the ICF
Have previously been treated with lenalidomide and are no longer on active treatment with lenalidomide at the time of signing the ICF

Where it is running

Local Institution - 0002 — Centre City, New Jersey, United States
Local Institution - Belgium — No City Provided, New Jersey, United States
Local Institution - Denmark — No City Provided, New Jersey, United States
Local Institution - France — No City Provided, New Jersey, United States
Local Institution - Germany — No City Provided, New Jersey, United States
Local Institution - Greece — No City Provided, New Jersey, United States
Local Institution - Italy — No City Provided, New Jersey, United States
Local Institution - Luxembourg — No City Provided, New Jersey, United States
Local Institution - Norway — No City Provided, New Jersey, United States
Local Institution - Spain — No City Provided, New Jersey, United States
Local Institution - Sweden — No City Provided, New Jersey, United States
Local Institution - UK — No City Provided, New Jersey, United States
AZ Klina — Brasschaat, Belgium
AZ Sint Jan — Bruges, Belgium
GHdCharleroi — Charleroi, Belgium
Jessa Ziekenhuis — Hasselt, Belgium
CHR Citadelle — Liège, Belgium
CHU Vésale — Montigny-le-Tilleul, Belgium
Clinique Saint-Pierre Ottignie — Ottignies, Belgium
Aalborg Sygehus, Dept of Hematology — Aalborg, Denmark
Århus University Hospital — Aarhus, Denmark
Herlev Hospital — Herlev, Denmark
Odense University Hospital — Odense, Denmark
Rokslide Hospital — Roskilde, Denmark
Local Institution - 0001 — Centre City, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.